# LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome

> **NCT07234695** · PHASE3 · RECRUITING · sponsor: **Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau** · enrollment: 120 (estimated)

## Conditions studied

- Down Syndrome
- Down Syndrome (DS)
- Down Syndrome (Trisomy 21)
- Alzheimer Dementia
- Alzheimer Dementia (AD)
- Alzheimer Disease
- Alzheimer Disease (AD)
- Alzheimer Blood Biomarkers
- Epilepsy
- Seizures

## Interventions

- **DRUG:** Levetiracetam 500mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07234695
- **Lead sponsor:** Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-22
- **Primary completion:** 2027-12
- **Final completion:** 2028-07
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-01-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07234695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07234695, "LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07234695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*